With India’s services sector showing strong growth that offsets softer manufacturing and lifts its composite PMI, investors now see how much difference consistent earnings expansion can make when other areas of the economy feel patchy. That is exactly where the Healthy high growth potential screener comes in. It highlights companies where analysts expect solid earnings growth and reasonable balance sheets. This article walks through three stocks that currently match that profile.
The three stocks covered below are just a sample from this healthy high growth potential idea. The full screen surfaced 282 more companies with similarly compelling earnings and balance sheet profiles that are not discussed here. To go straight to the source and identify which of those candidates best fit your own criteria, analyze the Healthy high growth potential screener.
Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals is a US based clinical stage biotech company focused on treatments for neurodegenerative diseases and rare endocrine conditions, with its Healthy high growth potential link coming from late stage programs like AMX0114 and AMX0035 aiming at serious disorders such as ALS and progressive supranuclear palsy. As a pre commercial company, it is not yet reporting product revenue. The story centers on future earnings potential rather than current sales. Amylyx currently carries a market cap of about US$4.4b.
Investors looking at Amylyx Pharmaceuticals are really looking at a turning point story. Positive Phase 3 LUCIDITY data for avexitide in post bariatric hypoglycemia and plans to file an NDA by the end of 2026 put the company closer to its first meaningful revenue stream. AMX0114 and AMX0035 provide additional potential opportunities in high need neurodegenerative diseases. The trade off is clear. Amylyx is still loss making, relies on external capital and has recently raised US$500 million of new equity, so clinical or regulatory setbacks could affect both earnings potential and shareholder dilution. The key issue for investors is whether the emerging product franchise can justify the growth expectations already being built into forecasts.
Amylyx looks like a classic earnings acceleration story waiting for confirmation, yet the real twist may sit in the fine print of its trial pipeline and funding needs. Get the full context in the analysis report for Amylyx Pharmaceuticals
Build your own high growth shortlist around stories like Amylyx
Amylyx Pharmaceuticals and the two other stocks in this article all came from the same screening approach, which you can easily adapt to your own style. Use our flexible Screener to mix filters for growth, quality and balance sheets, or start with one of our curated Investing Ideas for ready made stock shortlists.
MercadoLibre (MELI)
MercadoLibre runs the leading online marketplace and fintech ecosystem across Brazil, Mexico, Argentina and other Latin American countries, combining e commerce, logistics and digital financial services. Its strongest link to the Healthy high growth potential theme is Mercado Pago, which drives earnings growth through digital payments, credit via Mercado Crédito and investment products through Mercado Fondo, even though the broader marketplace and logistics operations still carry meaningful weight. The company generated about US$35.2b of revenue from Internet Software & Services and has a market cap of roughly US$97.4b.
MercadoLibre provides exposure to one of the most prominent growth stories in Latin American fintech, with Mercado Pago, Mercado Crédito and Mercado Fondo contributing to forecasts for earnings growth of around 29% a year over the next three years. At the same time, the stock trades at a significant discount to Simply Wall St’s DCF estimate of fair value, which is relevant if that growth is reflected in cash flows as the expanding credit book matures. However, margins have come under pressure and the business uses high levels of external debt rather than customer deposits, so funding costs and credit quality remain key watchpoints. For investors seeking a case study in how a fast growing fintech can appear expensive on a simple P/E while still potentially offering upside for those with a long term view, MercadoLibre may warrant closer examination.
MercadoLibre’s earnings engine and credit growth story often look at odds with its valuation. Before you assume the market already sees it all, review the analyst forecasts for MercadoLibre and see what might be missing
Fabrinet (FN)
Fabrinet is a manufacturing partner for high speed optical components and electromechanical systems, with its strongest link to the Healthy high growth potential theme coming from making optical transceivers, tunable lasers, transponders and active optical cables used in data centers and telecom networks. Almost all of its revenue, about US$4.6b, comes from optical networking equipment for original equipment manufacturers across communications, industrial, automotive, medical and sensor markets worldwide. Fabrinet currently has a market cap of roughly US$15.9b.
Investors looking at Fabrinet are weighing the appeal of exposure to data center and AI driven demand against a set of concentration and execution risks. The company is tightly connected to cloud and telecom capacity buildouts through its optical interconnect products, a large share of sales is tied to a small group of customers, and ongoing capacity expansion could pressure cash flow if demand cools. Recent index additions and partnerships in high performance computing highlight Fabrinet’s role in this supply chain, while margin swings, supply bottlenecks and insider selling mean you need to consider carefully how much volatility you are prepared to accept.
Fabrinet’s AI driven demand story can appear powerful, while concentration and capacity risks remain in the background. Get the fuller picture in the 3 key rewards and 3 important warning signs (1 is major!)
Seeking Fresh Alternatives Before Momentum Flies
Breakout stories can move fast and drop off the radar just as quickly. Scan fresh stock ideas before the crowd while it matters and get in early.
- Spot dividend engines that aim to keep cash flowing even when prices wobble by running your filters through the 12 dividend fortresses.
- Hunt for smaller AI stocks that already earn real profits instead of burning cash by screening with the 76 profitable AI stocks that aren't just burning cash.
- Target companies with strong balance sheets that may handle shocks better than most by checking the list of solid balance sheet and fundamentals (50 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com